Lucid Diagnostics Inc.
Close on Oct 19, 2026
- Market cap
- $69.11M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 11, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | $1.50M | $-0.08 | $-0.06 |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | Before market open | $1.26M | $-0.17 | $-0.07 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | Before market open | $1.50M | $-0.12 | $-0.10 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | $1.20M | $-0.10 | $-0.10 |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 13, 2025 | Before market open | $1.20M | $-0.08 | $-0.10 |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | Before market open | $800.00K | $-0.52 | $-0.16 |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 25, 2025 | Before market open | $1.20M | $-0.20 | $-0.19 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | $1.20M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | After market close | – | – | – |
Press releases
Announcements Lucid Diagnostics filed with the SEC
Diagnostics Advances Multiple EsoGuard ® and EsoCheck ® Payment, Billing and Coding Pathways
Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Diagnostics Announces $18 Million Underwritten Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Announces Closing of Public Offering of Common Stock
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Diagnostics Announces Proposed Public Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Announces Pricing of Public Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Announces Closing of Public Offering of Common Stock
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Diagnostics Announces Proposed Public Offering of Common Stock
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Lucid Diagnostics Announces Pricing of Public Offering
Material agreement · Regulation FD disclosure · EX-99.2 to Form 8-K
Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Diagnostics Announces $15.3 Million Registered Direct Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and First Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Closes Series B / B-1 Preferred Stock Offering and Appoints Healthcare Industry Veteran Dennis Matheis to Board of Directors
Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical
Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and Third Quarter Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Update on Newly Published Future Effective Medicare Local Coverage Determination on Molecular Testing for Detection
Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and Fourth Quarter and Full Year 2022 Financial Results
Material agreement · Results of operations · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Holds First #CheckYourFoodTube Precancer Testing Event
Regulation FD disclosure · EX-99.1 to Form 8-K
and Lucid Diagnostics Provide Strategic Business Update
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and Preliminary Second Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Business Update and Preliminary First Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans
Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics Provides Updates on Newly Published Esophageal Precancer Clinical Guideline and Proposed Medicare Local Coverage Determination
Regulation FD disclosure · EX-99.1 to Form 8-K
Provides Business Update and Preliminary Fourth Quarter and Full Year 2021 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K/A
Diagnostics Provides Business Update and Preliminary
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics to Hold a Business Update Conference Call on March 28, 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Diagnostics to Participate in a Fireside Chat at the 24th Annual Needham Virtual Growth Conference
Regulation FD disclosure · EX-99.1 to Form 8-K
Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth
Regulation FD disclosure · EX-99.1 to Form 8-K